Research
Hormonal
Wegovy rose from 989 in 2021 to 2992 in 2022.
The increase in Wegovy usage suggests a rising interest in GLP-1 receptor agonists for weight loss.
StrongSupportsmedium confidence
Wegovy rose from 989 in 2021 to 2992 in 2022.
Why this rating
Based on the retrospective cohort study design involving a large database.
Source
Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022
Jonathan H. Watanabe et al. · Journal of the American Pharmacists Association · 2023
cohortCited 179×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →